Amyloid cascade in Alzheimer's disease: Recent advances in medicinal chemistry

被引:145
|
作者
Mohamed, Tarek [1 ,2 ]
Shakeri, Arash [1 ]
Rao, Praveen P. N. [1 ]
机构
[1] Univ Waterloo, Sch Pharm, Hlth Sci Campus,200 Univ Ave West, Waterloo, ON N2L 3G1, Canada
[2] Univ Waterloo, Dept Chem, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Alzheimer's disease; Amyloid cascade; Protein aggregation; Beta amyloid dimer; Amyloidogenic; Molecular docking; Steric-zipper assembly; PROTEIN MISFOLDING DISEASES; SMALL-MOLECULE INHIBITORS; TARGET-DIRECTED LIGANDS; BETA-SECRETASE; PRECURSOR PROTEIN; NEURODEGENERATIVE DISORDERS; RESVERATROL DERIVATIVES; AGGREGATION INHIBITOR; HUNTINGTONS-DISEASE; DIABETES-MELLITUS;
D O I
10.1016/j.ejmech.2016.02.049
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Alzheimer's disease is of major concern all over the world due to a number of factors including (i) an aging population (ii) increasing life span and (iii) lack of effective pharmacotherapy options. The past decade has seen intense research in discovering disease-modifying multitargeting small molecules as therapeutic options. The pathophysiology of Alzheimer's disease is attributed to a number of factors such as the cholinergic dysfunction, amyloid/tau toxicity and oxidative stress/mitochondrial dysfunction. In recent years, targeting the amyloid cascade has emerged as an attractive strategy to discover novel neurotherapeutics. Formation of beta-amyloid species, with different degrees of solubility and neurotoxicity is associated with the gradual decline in cognition leading to dementia. The two commonly used approaches to prevent beta-amyloid accumulation in the brain include (i) development of beta-secretase inhibitors and (ii) designing direct inhibitors of beta-amyloid (self-induced) aggregation. This review highlights the amyloid cascade hypothesis and the key chemical features required to design small molecules that inhibit lower and higher order beta-amyloid aggregates. Several recent examples of small synthetic molecules with disease-modifying properties were considered and their molecular docking studies were conducted using either a dimer or steric-zipper assembly of beta-amyloid. These investigations provide a mechanistic understanding on the structural requirements needed to design novel small molecules with anti-amyloid aggregation properties. Significantly, this work also demonstrates that the structural requirements to prevent aggregation of various amyloid species differs considerably, which explains the fact that many small molecules do not exhibit similar inhibition profile toward diverse amyloid species such as dimers, trimers, tetramers, oligomers, protofibrils and fibrils. (C) 2016 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:258 / 272
页数:15
相关论文
共 50 条
  • [31] Recent advances in synthesis and medicinal chemistry of benzodiazepines
    Arora, Nidhi
    Dhiman, Prashant
    Kumar, Shubham
    Singh, Gurpreet
    Monga, Vikramdeep
    BIOORGANIC CHEMISTRY, 2020, 97
  • [32] Recent advances in the medicinal chemistry of antifungal agents
    Turner, WW
    Rodriguez, MJ
    CURRENT PHARMACEUTICAL DESIGN, 1996, 2 (02) : 209 - 224
  • [33] Recent Advances in Medicinal Chemistry and Chemical Biology
    Boger, Dale L.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (21) : 4713 - 4713
  • [34] Overview of Recent Strategic Advances in Medicinal Chemistry
    Wu, Gaochan
    Zhao, Tong
    Kang, Dongwei
    Zhang, Jian
    Song, Yuning
    Namasivayam, Vigneshwaran
    Kongsted, Jacob
    Pannecouque, Christophe
    De Clercq, Erik
    Poongavanam, Vasanthanathan
    Liu, Xinyong
    Zhan, Peng
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (21) : 9375 - 9414
  • [35] Treatment of Alzheimer's Disease: Contemporary Perspectives in Medicinal Chemistry
    de Oliveira, Aldo Sena
    CURRENT MEDICINAL CHEMISTRY, 2023, 30 (06) : 667 - 668
  • [36] Advances in the β-amyloid precursor protein of Alzheimer's disease.
    Chen, PL
    Tong, TJ
    Zhang, ZY
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 1999, 26 (02) : 105 - 108
  • [37] Role of Amyloid-β and Tau Proteins in Alzheimer's Disease: Confuting the Amyloid Cascade
    Gulisano, Walter
    Maugeri, Daniele
    Baltrons, Marian A.
    Fa, Mauro
    Amato, Arianna
    Palmeri, Agostino
    D'Adamio, Luciano
    Grassi, Claudio
    Devanand, D. P.
    Honig, Lawrence S.
    Puzzo, Daniela
    Arancio, Ottavio
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 64 : S611 - S631
  • [38] Recent advances in the design and applications of amyloid-β peptide aggregation inhibitors for Alzheimer’s disease therapy
    Jokar S.
    Khazaei S.
    Behnammanesh H.
    Shamloo A.
    Erfani M.
    Beiki D.
    Bavi O.
    Biophysical Reviews, 2019, 11 (6) : 901 - 925
  • [39] Recent advances in nanoenzymes for Alzheimer's ' s disease treatment
    Bi, Xiaojun
    Cao, Ning
    He, Jingteng
    COLLOIDS AND SURFACES B-BIOINTERFACES, 2024, 244
  • [40] Recent advances in Alzheimer's disease and other dementias
    Rohrer, J. D.
    JOURNAL OF NEUROLOGY, 2013, 260 : S9 - S9